AAV-mediated gene transfer for hemophilia

Area of Science:

• Gene Therapy
• Hematology
• Molecular Biology

Background:

• Hemophilia is an inherited bleeding disorder caused by deficient clotting factors VIII or IX.
• Current treatments involve regular factor replacement therapy, which can be burdensome.

Purpose of the Study:

• To establish an experimental basis for gene transfer as a treatment for hemophilia.
• To evaluate the safety and efficacy of adeno-associated viral vector (AAV)-mediated gene transfer for hemophilia B.

Main Methods:

• Utilized an adeno-associated viral vector (AAV serotype 2) for gene transfer.
• Conducted studies in hemophilic mice and dogs, and a Phase I human trial.
• Assessed gene transfer and expression using PCR, Southern blot, and immunohistochemistry.
• Compared gene delivery via intramuscular injection versus portal vein infusion in dogs.

Main Results:

• Achieved long-term (>3 years) clotting factor expression in animal models, improving clinical symptoms.
• Phase I trial of intramuscular AAV-F.IX showed no local or systemic toxicity.
• Muscle biopsies confirmed gene transfer and expression.
• Liver-directed gene transfer in dogs resulted in significantly higher circulating factor IX levels (5-14%) compared to muscle delivery (1-2%).

Conclusions:

• AAV-mediated gene transfer is a viable strategy for long-term treatment of hemophilia.
• Liver-directed gene transfer demonstrates superior efficacy for achieving therapeutic factor IX levels.
• Further clinical trials of AAV-mediated liver-directed gene transfer for hemophilia B are warranted.